Free Trial
NASDAQ:INM

InMed Pharmaceuticals Q3 2025 Earnings Report

InMed Pharmaceuticals logo
$2.98 -0.34 (-10.24%)
As of 06/4/2025 04:00 PM Eastern

InMed Pharmaceuticals EPS Results

Actual EPS
-$1.94
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

InMed Pharmaceuticals Revenue Results

Actual Revenue
$1.26 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InMed Pharmaceuticals Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Sunday, May 11, 2025
Conference Call Time
6:00PM ET

InMed Pharmaceuticals Earnings Headlines

Best Cannabis Stocks To Follow Now - June 2nd
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
See More InMed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InMed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMed Pharmaceuticals and other key companies, straight to your email.

About InMed Pharmaceuticals

InMed Pharmaceuticals (NASDAQ:INM), a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

View InMed Pharmaceuticals Profile

More Earnings Resources from MarketBeat